Therapeutic potential of amnion epithelial cells for diabetes

Chika Koike, Motonori Okabe, Toshiko Yoshida, Toshio Nikaido*

*この論文の責任著者

研究成果: 書籍の章/レポート/会議録査読

抄録

Whole pancreas, islet, or β-cell transplantation has been a treatment option for diabetes mellitus. However, the shortage of transplantation materials limits this transplantation therapy and new sources of insulin-producing cells are required. The amniotic membrane is a part of the fetal membrane and is composed of amniotic epithelium and mesenchymal cells that are derived from the inner cell mass in the blastocyst. It has been shown that human amniotic epithelial cells and mesenchymal cells have the potential to differentiate into various organs, have less immunologic activity, and are supposed to be cell sources for allogeneic transplantation. Several researchers have reported that amnion-derived cells differentiate into insulin-producing cells in vitro and/or the transplantation of amnion-derived cells normalized the blood glucose level in diabetes mice. Amnion-derived cells may be a good cell source for the transplantation therapy of diabetes.

本文言語英語
ホスト出版物のタイトルPerinatal Stem Cells
出版社Springer New York
ページ253-257
ページ数5
ISBN(電子版)9781493911189
ISBN(印刷版)1493911171, 9781493911172
DOI
出版ステータス出版済み - 2014/04/01

ASJC Scopus 主題領域

  • 生化学、遺伝学、分子生物学一般

フィンガープリント

「Therapeutic potential of amnion epithelial cells for diabetes」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル